Literature DB >> 8069299

Alternative splicing of the NF2 gene and its mutation analysis of breast and colorectal cancers.

H Arakawa1, N Hayashi, H Nagase, M Ogawa, Y Nakamura.   

Abstract

To investigate a potential role of NF2, the gene responsible for hereditary bilateral acoustic neurinomas, during carcinogenesis of non-neurogenic tissues, we screened somatic mutations of NF2 in 55 breast cancers and 44 colorectal carcinomas by an RNase protection assay coupled with the reverse-transcriptase polymerase chain reaction (RT-PCR). By screening the entire coding region of the gene in these tumors, we detected missense mutations in the exon encoding the alpha-helical domain of the NF2 product in two colorectal carcinomas. No mutations were detected in any of the breast cancers. Our results suggested that inactivation of the NF2 gene was associated with carcinogenesis in some, but not the majority of, colorectal tumors. In the course of these analyses, we found various alternatively-spliced forms of NF2 transcript. These variants showed no specificity among the tissues examined except for one that resulted from alternative splicing at the 3'-region; this form was more abundantly expressed in skeletal and cardiac muscles than in other tissues.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8069299     DOI: 10.1093/hmg/3.4.565

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  28 in total

1.  Analysis of the neurofibromatosis type 2 gene in different human tumors of neuroectodermal origin.

Authors:  L R De Vitis; A Tedde; F Vitelli; F Ammannati; P Mennonna; P Bono; B Grammatico; P Grammatico; P Radice; U Bigozzi; E Montali; L Papi
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

2.  Effects of splicing mutations on NF2-transcripts: transcript analysis and information theoretic predictions.

Authors:  James R Ellis; Bianca Heinrich; Victor-F Mautner; Lan Kluwe
Journal:  Genes Chromosomes Cancer       Date:  2011-05-11       Impact factor: 5.006

3.  Eleven novel mutations in the NF2 tumour suppressor gene.

Authors:  D Bourn; G Evans; S Mason; S Tekes; L Trueman; T Strachan
Journal:  Hum Genet       Date:  1995-05       Impact factor: 4.132

4.  Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation.

Authors:  K Adam Morrow; Shamik Das; Brandon J Metge; Keqiang Ye; Madhuri S Mulekar; J Allan Tucker; Rajeev S Samant; Lalita A Shevde
Journal:  J Biol Chem       Date:  2011-09-30       Impact factor: 5.157

5.  Functional analysis of the neurofibromatosis type 2 protein by means of disease-causing point mutations.

Authors:  R P Stokowski; D R Cox
Journal:  Am J Hum Genet       Date:  2000-03       Impact factor: 11.025

6.  Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins.

Authors:  L Goutebroze; E Brault; C Muchardt; J Camonis; G Thomas
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

7.  Loss of NF2/Merlin expression in advanced sporadic colorectal cancer.

Authors:  Tamara Cačev; Gorana Aralica; Božo Lončar; Sanja Kapitanović
Journal:  Cell Oncol (Dordr)       Date:  2013-12-10       Impact factor: 6.730

8.  High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.

Authors:  A B Bianchi; S I Mitsunaga; J Q Cheng; W M Klein; S C Jhanwar; B Seizinger; N Kley; A J Klein-Szanto; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

9.  Loss of heterozygosity on long arm of chromosome 22 in sporadic colorectal carcinoma.

Authors:  Chong-Zhi Zhou; Zhi-Hai Peng; Fang Zhang; Guo-Qiang Qiu; Lin He
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

10.  Identification of three neurofibromatosis type 2 (NF2) gene mutations in vestibular schwannomas.

Authors:  J Sainz; K Figueroa; M E Baser; S M Pulst
Journal:  Hum Genet       Date:  1996-01       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.